Effect of Oral Aminophylline on Pulmonary Function Improvement and Tolerability in Different Age Groups of COPD Patients*

Cheng-Yu Chen, Kuang-Yao Yang, Yu-Chin Lee and Peury-Perng Perng Chest 2005;128;2088-2092 DOI 10.1378/chest.128.4.2088 The online version of this article, along with updated information and services can be found online on the World Wide Web at: http://chestjournal.chestpubs.org/content/128/4/2088.full.html

Chest is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright2005by the American College of Chest Physicians, 3300 Dundee Road, Northbrook, IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder. (http://chestjournal.chestpubs.org/site/misc/reprints.xhtml) ISSN:0012-3692

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians

Effect of Oral Aminophylline on Pulmonary Function Improvement and Tolerability in Different Age Groups of COPD Patients*
Cheng-Yu Chen, MD; Kuang-Yao Yang, MD; Yu-Chin Lee, MD; and Peury-Perng Perng, MD, PhD

Background: Aminophylline therapy in elderly patients with COPD is rarely studied. This study attempted to explore the symptoms, pulmonary function improvement, and adverse events related to aminophylline therapy in COPD patients of different age groups. Methods and results: We designed a 10-week prospective study. Two groups of COPD patients were classified based on age (30 patients in group 1, 55 to 74 years old; 30 patients in group 2, 75 to 90 years old), with matched disease severity. After stopping all methylxanthines for 2 weeks in the washout period, therapy began with long-acting 225-mg aminophylline compounds bid po for 8 weeks. Pulmonary functions, respiratory symptoms, and laboratory examinations were checked at the initial visit and at every 4-week visit. After aminophylline therapy, the drug serum level showed no significant difference in either group (9.73 6.35 mg/dL [ SD] in group 1 and 7.82 6.68 mg/dL in group 2, p 0.359). Improvements of FEV1 and FVC were noted in both groups; however, there was no significant difference. Peak expiratory flow rate (PEFR) was significantly improved in group 1 but not in group 2 (group 1, from 3.51 to 3.97 L/s, p < 0.05; group 2, from 2.78 to 3.08 L/s, p > 0.05). The degree of improvement in symptom scores was not different between the groups, except there was significantly less chest tightness in group 2 (from 0.79 0.74 to 0.40 0.50, p < 0.05). Electrolyte imbalance and arrhythmia did not appear in either group. Conclusions: Our study demonstrated that the safety and drug concentration of aminophylline at a standard dose are not different in the sixth to ninth decades of COPD patients. Younger patients have more improvement in PEFR than older patients; however, older COPD patients have more symptoms relief in chest tightness after aminophylline therapy. (CHEST 2005; 128:2088 2092)
Key words: age; aminophylline; COPD; pulmonary function; side effect Abbreviations: Dlco diffusing capacity of the lung for carbon monoxide; PEFR peak expiratory flow rate

T heophylline is a methylxanthine similar in structure to the common dietary xanthines caffeine

and theobromine. Aminophylline is the ethylenediamine salt of theophylline with higher solubility at a neutral pH. Aminophylline has been indicated for the treatment of asthma and COPD for 50 years,
*From the Institute of Emergency and Critical Medicine (Dr. Chen), Institute of Clinical Medicine (Dr. Yang), and School of Medicine (Dr. Lee), National Yang-Ming University; and Chest Department (Dr. Perng), Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Manuscript received November 10, 2004; revision accepted March 1, 2005. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal. org/misc/reprints.shtml). Correspondence to: Kuang-Yao Yang, MD, Chest Department, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Rd, Taipei, Taiwan, ROC; e-mail: kyyang@vghtpe.gov.tw
2088

and remains one of the most widely prescribed drugs for the treatment of obstructive airway diseases, as it is inexpensive. Accumulating evidence indicates that IV aminophylline has many side effects, and is of less benefit in acute exacerbations of COPD.1 In many industrialized countries, however, theophylline has become a second-line treatment that is used only for some poorly controlled patients. This has been reinforced by various guidelines for COPD therapy. The frequency of side effects and the relatively low efficacy of theophylline have recently led to reduced usage, because inhaled 2-agonists are far more effective as fast-onset bronchodilators, and inhaled corticosteroids have a greater anti-inflammatory effect.2,3 However, adding theophylline can decrease the dosage of inhaled corticosteroid in the control of moderate COPD.4
Clinical Investigations

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians

Aminophylline is absorbed rapidly after oral administration. Peak serum levels occur in 1.5 to 2 h. The half-life is 4 to 8 h in young adults, and is shorter in children and smokers. Theophylline is eliminated by the hepatic cytochrome P-450 system (85 to 90%) and urinary excretion (10 to 15%). Diet, cardiac or liver disease, tobacco use, and several medications affecting the cytochrome P-450 system can affect the half-life of theophylline. Therapeutic serum levels range from 10 to 20 g/mL. Toxic levels are considered to be those 20 g/mL; however, medication, diet, and underlying diseases can alter the narrow therapeutic window of theophylline, and adverse effects may also occur within the normal therapeutic range.5 Theophylline affects the cardiovascular, neurologic, GI, and metabolic systems. Hypokalemia, hyperglycemia, hypercalcemia, hypophosphatemia, and acidosis commonly occur after an acute overdose.5 In the United States, the 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System documented 585 theophylline overdose exposures treated in health-care facilities; 39 exposures were reported to have major adverse outcomes, and eight fatalities were noted.6 The age population of COPD patients is always 50 years old, and the reduced-dose usage of theophylline is often recommended in these elderly people. Therefore, in this study, we explored the efficacy and safety of aminophylline in elderly COPD patients, and compared the differences between the 75-year-old group and the senior group.

Table 1Scores for Sleep Disturbance, Breathlessness, Cough, and Chest Tightness*
Symptoms Nighttime: sleep disturbance No symptoms; slept through the night Woke once for a short while due to dyspnea Woke more than once due to dyspnea, but slept in-between Awake most but not all of the night due to dyspnea Did not sleep at all. Awake all night due to dyspnea Daytime: breathlessness, cough, chest tightness No breathlessness, cough, or chest tightness at all Slight symptoms without interfering with usual daily activity Moderate symptoms interfered, to some extent, with usual daily activity Severe symptoms definitely noticeable and interfered a lot with usual daily activity Symptoms very bad and unable to carry out usual daily activities or go to work *From Aalbers et al.8 Total score, 0 to 16. Scores 0 1 2 3 4 0 1 2 3 4

Materials and Methods

We designed a 10-week prospective study, and patients were enrolled from March 2002 to September 2002. Patients who fulfilled the 2001 Global Initiative for Chronic Obstructive Lung Disease guidelines for moderate COPD7 and who had 30 to 80% FEV1 predicted values on the first visit were enrolled into the study. The exclusion criteria were an exacerbation of the disease status within the recent 2 months, a 12% FEV1 increase after a bronchodilator test, and the presence of chronic renal and heart disease. We used an adherence-to-protocol analysis, and the study population comprised 60 patients classified into two groups based on age (30 patients in group 1, 55 to 74 years old; 30 patients in group 2, 75 to 90 years old). After stopping all methylxanthines for a 2-week washout period, the patients underwent lung function testing including diffusing capacity of the lung for carbon monoxide (Dlco). Long-acting aminophylline compounds were then administered, 225 mg bid po for 8 weeks, and other medications for COPD currently in use were continued. The severity of daily respiratory symptoms, including sleep disturbance and daytime symptoms (breathlessness, cough and chest tightness), were each given a score of 0 to 4, where 0 denoted no symptoms and 4 indicated the greatest severity (Table 1). This scoring system has also been adapted by a clinical trial8 of formoterol in patients with COPD. Pulmonary function and laboratory examinations were checked at every 4-week visit. The protocol was approved by the research
www.chestjournal.org

and ethical committees of our hospital, and all informed consents were obtained from the patients. For the statistical analysis, the study was designed with a sample size of 60 completed, per protocol, to achieve at least 80% power, in order to detect a 0.35-L difference of FVC and 1.0 difference of total symptom score. Baseline characteristics were compared using unpaired t tests for continuous variables and 2 tests for categorical variables. The mixed-factorial, two-way analysis of variance was used to evaluate the effect of aminophylline treatment, the difference in the two age groups, and the interaction of these two factors in the 60 COPD patients. The post hoc tests for differences between before and after treatment in each group were determined by Dunn (Bonferroni) correction. A p value 0.05 was considered statistically significant. All analyses were carried out using statistical software (GB-STAT, Version 6.0; Dynamic Microsystems; Silver Spring, MD).

Results The demographic characteristics of the patients in the two age groups are shown in Table 2. The mean age of the patients in group 1 was 64.2 years (SD, 6.3; range, 55 to 74 years), and in group 2 was 80.1 years (SD, 4.6; range, 75 to 90 years). There were no statistical differences in the body mass index, heart rate, and respiratory rate in the two groups. Although the baseline actual values of FEV1, FVC, and peak expiratory flow rate (PEFR) were higher in group 1 (1.31, 2.27, and 3.51 L/s, respectively) than in group 2 (1.09, 1.85, and 2.78 L/s, respectively), the percentage of predicted values was not different. Other pulmonary function parameters, including FEV1/ FVC, functional residual capacity, residual volume, total lung capacity, and Dlco, did not differ between the two groups. After 2 months of therapy with aminophylline, the
CHEST / 128 / 4 / OCTOBER, 2005

2089

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians

Table 2Demographic Characteristics at Baseline*

Characteristics Age, yr Body weight, kg Height, cm Body index (body weight/height2) Heart rate, beats/min Systolic/diastolic BP, mm Hg Ex-smokers Current smokers Nonsmokers Medication in use 2-Agonists Anticholinergics Inhaled corticosteroid Mucolytic drugs FEV1 Actual value, L Percentage of predicted value, % FVC Actual value, L Percentage of predicted value, % FEV1/FVC PEFR, L/s Functional residual capacity, L Residual volume, L Total lung capacity, L Dlco, mL/mm Hg/min Group 1 (n 30) 64.2 6.3 65.8 6.4 165.5 4.8 24.0 1.1 82 12 146/94 20 8 2 29 28 14 24 1.31 51.2 2.27 63.1 0.57 3.51 3.17 2.31 5.95 20.5 0.53 14.1 0.66 18.2 0.14 1.60 0.97 0.61 2.10 5.5 1.09 52.4 1.85 61.3 0.59 2.78 2.99 2.12 5.82 18.2 Group 2 (n 30) 80.1 4.6 63.4 4.3 163.2 4.7 23.7 1.9 85 14 150/92 26 3 1 28 29 17 21 0.39 10.9 0.48 15.6 0.13 0.97 1.01 0.72 1.91 4.3

Table 3Changes of Lung Functions After Aminophylline Treatment

Difference Related to Baseline, % Parameters* FEV1 Group 1 Baseline Treatment Group 2 Baseline Treatment FVC Group 1 Baseline Treatment Group 2 Baseline Treatment FEV1/FVC Group 1 Baseline Treatment Group 2 Baseline Treatment PEFR Group 1 Baseline Treatment Group 2 Baseline Treatment Data Mean 95% Confidence Interval

1.31 1.44 1.09 1.16

0.53 0.56 0.39 0.36

11.1

0.3 to 22.4

8.6

0 to 17.3

2.27 2.41 1.85 1.96

0.66 0.58 0.48 0.42

9.0

0.2 to 17.8

8.2

1.4 to 17.8

0.57 0.58 0.59 0.58

0.14 0.14 0.13 0.10

2.8

5.8 to 11.4

2.3

7.1 to 11.7

*Data at baseline were measured after washout period; data are shown as mean SD or No. Group 1, 30 patients (age 55 to 74 years). Group 2, 30 patients (age 75 to 90 years). p 0.05, unpaired t tests for continuous variables and 2 tests for categorical variables between the two groups.

3.51 3.97 2.78 3.08

1.60 1.72 0.97 1.10

15.4

5.6 to 25.3

12.3

2.3 to 22.4

serum theophylline levels showed no significant difference in both groups (9.73 6.35 mg/dL in group 1 and 7.82 6.68 mg/dL in group 2, p 0.359). Pulmonary function before and after treatment in the two groups is summarized in Table 3. FEV1 was increased after aminophylline therapy in the patients of group 1 (1.31 to 1.44 L) and the group 2 patients (1.09 to 1.16 L), but neither of them had statistic significance. PEFR was significant increased in group 1 (3.51 to 3.97 L/s, p 0.05) but not in group 2 (2.78 to 3.08 L/s). The symptom scores and electrolytes before and after treatment were summarized in Table 4. Group 2 showed more severe symptom scores with borderline statistic significance (p 0.062). There was no significant improvement in sleep disturbance, breathlessness, and cough in both groups. However, the patients of group 2 showed significantly abated chest tightness after treatment (from 0.79 0.74 to 0.40 0.50, p 0.05). Slight decreasing serum levels of sodium and potassium were related to treatment, but not significantly, and were not affected by age. Neither electrolyte imbalance nor arrhythmia was found on either group in the study period.
2090

*Group 1, 30 patients (age 55 to 74 years); group 2, 30 patients (age 75 to 90 years). Data are shown as mean SD. Indicates p 0.05 for the difference in pulmonary function before and after treatment, determined by Dunn (Bonferroni) correction.

Discussion For years, aminophylline has been recommended for use as a bronchodilator in many COPD treatment guidelines7,9 14; more recently, the 2003 Global Initiative for Chronic Obstructive Lung Disease9 suggested methylxanthines as a long-acting bronchodilator for moderate-to-severe COPD management. IV aminophylline dosage adjustments based on age and underlining medical conditions have been documented,15 but there is no real recommendation for an oral aminophylline dosage in the current literature. Au et al16 reported elderly ( 60 years old) COPD patients receiving IV aminophylline had a 36% lower theophylline clearance and a 40% longer serum theophylline elimination half-life than did patients 60 years old. However, Armijo et al17 reported the differential pharmacokinetics of oral aminophylline in elderly COPD patients aged 60 to
Clinical Investigations

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians

Table 4 Changes of Symptom Scores and Electrolytes After Aminophylline Treatment

Difference Related to Baseline, % Parameters* Sleep disturbance Group 1 Baseline Treatment Group 2 Baseline Treatment Breathlessness Group 1 Baseline Treatment Group 2 Baseline Treatment Cough Group 1 Baseline Treatment Group 2 Baseline Treatment Chest tightness Group 1 Baseline Treatment Group 2 Baseline Treatment Total symptom score Group 1 Baseline Treatment Group 2 Baseline Treatment Sodium Group 1 Baseline Treatment Group 2 Baseline Treatment Potassium Group 1 Baseline Treatment Group 2 Baseline Treatment Data Mean 95% Confidence Interval

0.85 0.58 1.19 1.09

071 0.62 0.95 0.70

12.0

80.3 to 104.2

13.4

53.0 to 79.8

1.16 0.96 1.41 1.13

0.86 0.75 1.00 0.93

21.0

69.7 to 111.6

19.3

50.6 to 12.0

1.01 0.60 1.28 0.96

0.65 0.48 0.86 0.59

28.1

51.9 to

4.4

18.8

37.9 to 0.4

0.55 0.25 0.79 0.40

0.69 0.45 0.74 0.50

22.4

43.6 to

1.2

41.2

68.5 to

13.8

3.56 2.33 4.64 3.55

2.08 1.40 2.28 2.18

18.3

44.1 to

7.6

13.1

39.9 to 13.7

142.69 142.13 142.19 140.63

2.12 1.50 2.88 3.30

0.4

1.2 to 0.4

1.1

2.3 to 0.1

4.49 4.26 4.42 4.23

0.37 0.43 0.57 0.47

5.0

9.3 to

0.7

3.8

8.3 to 0.7

*Group 1, 30 patients (age 55 to 74 years); group 2, 30 patients (age 75 to 90 years). Data are shown as mean SD. Indicates p 0.05 for the difference in the symptom before and after treatment, determined by Dunn (Bonferroni) correction.

87 years, and there was no significant correlation between the patient age and drug clearance within this elderly population. Although elderly patients have several risk factors that may increase the serum theophylline level, such as reduced drug clearance, cardiovascular diseases, and multiple concomitant medication,16 we demonstrated no significant difference of the theophylline serum levels after 2 months of aminophylline treatment in different old-age groups. Since COPD more commonly occurs in men, and most patients at Taipei Veterans General Hospital are elderly Chinese men, all of the patients in this study were Chinese men 55 years old. Until now, no scientific data have demonstrated that aminophylline toxicity is specific to race or gender. There was no significant interaction of age and oral long-acting aminophylline treatment in COPD patients; however, further post hoc tests revealed a significant improvement of PEFR in group 1 and relief of symptom of chest tightness in group 2 (Tables 3 and 4). The improvement of PEFR indicated that the caliber of the airways was significantly dilated in relatively younger COPD patients. The treatment responses of PEFR and FEV1 were not equivalent, and FEV1 showed a smaller degree of improvement in all patients. The degree of improvement of FVC and FEV1 were similar; hence, FEV1/FVC ratios were almost constant during treatment. The symptoms of COPD are related to lung hyperinflation, airflow limitation, and airway hyperreactivity. All of the symptoms were improved in most patients after treatment, but only relief of chest tightness in group 2 reached statistic significant level. A study18 of asthma concluded that the symptom of chest tightness in obstructive lung disease was caused by airway receptors stimulation, while others19 suggested that the chest tightness was related to lung hyperinflation and airflow limitation. No significant adverse event, such as arrhythmia, anxiety, nausea, or vomiting, was noted during the study period. Electrolytes were essentially normal, although the potassium concentration slightly decreased approximately 5%, even within the normal range, in patients in group 1. However, a recent large-scale prospective study20 in Japan suggested that sustained-release theophylline can be used safely in elderly patients ( 65 years old) with asthma or COPD. Our study has some limitation. The lack of a placebo-control group may complicate the interpretation of this open study, but it is also an ethical issue. Another problem is the relative short duration of the study, which may not provide strong evidences on the long-term safety of oral aminophylline. Others10,12 assume that longer treatment may lead to
CHEST / 128 / 4 / OCTOBER, 2005

www.chestjournal.org

2091

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians

further electrolyte imbalance. Thus, more large-scale randomized control studies may be necessary to answer these issues. In conclusion, when oral, long-acting aminophylline is used in elderly COPD patients, dosage adjustment may not be a requisite. Our study demonstrated that the safety and drug concentration of aminophylline at a standard dose did not differ from the sixth to ninth decades of life. Younger COPD patients have more improvement in PEFR than older patients; however, older COPD patients have more symptoms relief in chest tightness after aminophylline therapy.
ACKNOWLEDGMENT: The authors thank Professor Yu-Ru Kou for his help with statistic analysis.

9 10

11 12

13 14

References
1 Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomized trials. BMJ 2003; 327:643 646 2 Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003; 63:1973 1998 3 Altose MD. Approaches to slowing the progression of COPD. Curr Opin Pulm Med 2003; 9:125130 4 Van Andel AE, Reisner C, Menjoge SS, et al. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999; 115:703707 5 Elenbaas RM, Payne VW. Prediction of serum theophylline levels. Ann Emerg Med 1984; 13:9296 6 Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:352 421 7 Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative 15

16 17

18 19 20

for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256 1276 Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19:936 943 Lenfant C. Global Initiative for Chronic Obstructive Lung Disease executive summary. 2004; 1 41 Yohannes AM, Hardy CC. Treatment of chronic obstructive pulmonary disease in older patients: a practical guide. Drugs Aging 2003; 20:209 228 MacNee W, Calverley PM. Chronic obstructive pulmonary disease: 7. Management of COPD. Thorax 2003; 58:261265 Cydulka RK, Rowe BH, Clark S, et al. Emergency department management of acute exacerbations of chronic obstructive pulmonary disease in the elderly: the Multicenter Airway Research Collaboration. J Am Geriatr Soc 2003; 51:908 916 Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813 818 Sutherland ER, Cherniack RM. Current concepts: management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2689 2697 Lau AH, OConnor T, Lam G, et al. Rapid estimation of total body clearance of theophylline in patients receiving intravenous aminophylline infusion. Int J Clin Pharmacol Ther Toxicol 1986; 24:1215 Au WY, Dutt AK, DeSoyza N. Theophylline kinetics in chronic obstructive airway disease in the elderly. Clin Pharmacol Ther 1985; 37:472 478 Armijo JA, Sanchez BM, Peralta FG, et al. Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications. Biopharm Drug Dispos 2003; 24:165171 Binks AP, Moosavi SH, Banzett RB, et al. Tightness sensation of asthma does not arise from the work of breathing. Am J Respir Crit Care Med 2002; 165:78 82 Killian KJ, Watson R, Otis J, et al. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000; 162:490 496 Ohta K, Fukuchi Y, Grouse L, et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 2004; 98:1016 1024

2092

Clinical Investigations

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians

Effect of Oral Aminophylline on Pulmonary Function Improvement and Tolerability in Different Age Groups of COPD Patients * Cheng-Yu Chen, Kuang-Yao Yang, Yu-Chin Lee and Peury-Perng Perng Chest 2005;128; 2088-2092 DOI 10.1378/chest.128.4.2088 This information is current as of June 2, 2012
Updated Information & Services Updated Information and services can be found at: http://chestjournal.chestpubs.org/content/128/4/2088.full.html References This article cites 19 articles, 8 of which can be accessed free at: http://chestjournal.chestpubs.org/content/128/4/2088.full.html#ref-list-1 Permissions & Licensing Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.chestpubs.org/site/misc/reprints.xhtml Reprints Information about ordering reprints can be found online: http://www.chestpubs.org/site/misc/reprints.xhtml Citation Alerts Receive free e-mail alerts when new articles cite this article. To sign up, select the "Services" link to the right of the online article. Images in PowerPoint format Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online figure for directions.

Downloaded from chestjournal.chestpubs.org by guest on June 2, 2012 2005 American College of Chest Physicians